Feds Sue Pharma Douche Over AIDS Drug Price Hike

Reuters reports:

Martin Shkreli, the “pharma bro” in prison for defrauding investors, faces a lawsuit filed by the Federal Trade Commission and New York attorney general’s office for an alleged scheme to preserve his monopoly for the drug Daraprim, whose price increased by more than 4,000% in one day.

The lawsuit accuses a company that Shkreli once ran of buying the rights in 2015 to Daraprim, which is used to treat toxoplasmosis – a disease resulting from infection with a parasite – and quickly raising the price from $17.50 per tablet to $750 while taking steps to ensure there would not be a cheaper generic version of the medicine.

A lawyer for Shkreli, 36, did not respond to a request for comment. Shkreli is slated for release in September 2023, according to the Federal Bureau of Prisons.